02.08.2023 - – Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA autoinjector launched in late May, and YUSIMRY launched in July –– Planned merger with Surface Oncology .
Coherus to Acquire Surface Oncology - Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple. | June 16, 2023
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing. | June 16, 2023
Coherus BioSciences, Inc : Coherus to Acquire Surface Oncology finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Coherus to Acquire Surface Oncology - Surface Oncology (NASDAQ:SURF), Coherus BioSciences (NASDAQ:CHRS) benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.